Skip to Content
Merck
All Photos(1)

Key Documents

More Documents

SML2052

Sigma-Aldrich

LCAT activator compound A

≥98% (HPLC)

Synonym(s):

3-[[5-(Ethylthio)-1,3,4-thiadiazol-2-yl]thio]-2-pyrazinecarbonitrile, 3-[[5-(Ethylthio)-1,3,4-thiadiazol-2-yl]thio]pyrazine-2-carbonitrile, Compound A

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C9H7N5S3
CAS Number:
1000269-30-6
Molecular Weight:
281.38
UNSPSC Code:
41106609
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

color

white to brown

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

CCSC1=NN=C(S1)SC2=NC=CN=C2C#N

Biochem/physiol Actions

LCAT activator compound A is an activator of Lecithin:cholesterol acyltransferase (LCAT) including some mutant LCATs found in Familial LCAT Deficiency (FLD). LCAT activator compound A forms a covalent hydrophobic adduct with LCAT Cys 31. The chronic treatment with LCAT activator compound A results in a significant increase in HDLc, HDL particle, size, plasma apolipoprotein A-I level, plasma cholesteryl ester to free cholesterol ratio, and a significant reduction in very low-density lipoprotein cholesterol in hamsters.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Zhu Chen et al.
Metabolism: clinical and experimental, 61(4), 470-481 (2011-10-18)
The objective was to assess whether pharmacological activation of lecithin cholesterol acyltransferase (LCAT) could exert beneficial effects on lipoprotein metabolism. A putative small molecule activator (compound A) was used as a tool compound in in vitro and in vivo studies.
Lita A Freeman et al.
The Journal of pharmacology and experimental therapeutics, 362(2), 306-318 (2017-06-04)
Lecithin:cholesterol acyltransferase (LCAT) catalyzes plasma cholesteryl ester formation and is defective in familial lecithin:cholesterol acyltransferase deficiency (FLD), an autosomal recessive disorder characterized by low high-density lipoprotein, anemia, and renal disease. This study aimed to investigate the mechanism by which compound

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service